Actinium Pharmaceuticals Inc.

Market cap: $268,389,232

Exchange: ASE

Sector: Health Technology

Share
Tweet

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. The firm provides its service through Iomab-B, which is studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company was founded in 2002 and is headquartered in New York, NY.

Key Statistics

Company Name

Actinium Pharmaceuticals Inc

Average Volume (10 days)

456,303

Average Volume (30 days)

606,671

Moving Average (50 days)

$7.75

Moving Average (200 days)

$5.87

Ex-Divided Date

n/a

Dividend Yield

0

P/E Ratio

0

Market Cap

268,389,232

Shares Outstanding

29,396,411

52-Week High Split Adjust Only

9.86

52-Week Low Split Adjust Only

4

Employee Count

56

Beta

0.7037

Next Earnings Date

2024-05-13

TTM Dividend Rate Per Share

0

Price Changes

Past 5 days

0.17%

Past 30 days

0.16%

Past 3 months

0.75%

Past 6 months

0.59%

Past year

0.02%

Past 2 years

0.72%

Past 5 years

-0.46%

Max % Change

82%

PEER GROUP COMPARATIVE PERFORMANCE

NameTickerPrice/Sales (ttm)Price/Book (ttm)Forward P/EPEG RatioEV/Revenue
Actinium Pharmaceuticals Inc.ATNMn/an/an/an/an/a
Peer AvgN/A10.751.29-29.910.756.29
Biomarin Pharmaceutical Inc. - Registered SharesBMRN7.663.39-151.27.667.65
Kamada LtdKMDAn/an/a34.5n/an/a
Advaxis, Inc.ADXS35.361.76-2.835.3617.49